Background {#Sec1}
==========

Cancer is the world's second leading cause of death and a major cause of disability. In 2013, an estimated 8.2 million individuals died of cancer, equating to 15% of all deaths globally \[[@CR1]\]. While cancer survival rates are improving in high-income countries, cancer mortality rates are particularly high in low- and middle-income countries (LMICs), largely because of delays in diagnosis leading to presentation with advanced disease \[[@CR2]\]. Breast cancer survival rates, for instance, range from 80% or higher in North America, Sweden and Japan to around 60% in middle-income countries and below 40% in low-income countries \[[@CR3]\]. In addition, cancer affects populations in LMICs at relatively young ages, resulting in long periods of ill-health, great loss of productivity, and premature deaths \[[@CR2], [@CR4]\]. The burden of cancer continues to increase because of the ageing and growth of the population alongside increasing levels of cancer-causing behaviors such as smoking, physical inactivity, and unhealthy dietary habits \[[@CR2]\]. Thus, cancer threatens health and economic development in LMICs and requires urgent attention \[[@CR5]--[@CR8]\].

The ACTION study was a longitudinal study of 9513 newly diagnosed cancer patients in eight LMICs in Southeast Asia, set up to prospectively assess the impact of cancer on households' economic wellbeing and health \[[@CR9]\]. Results of the study reported thus far have demonstrated that families living in Southeast Asia struggled to manage the costs associated with cancer care; over half the households faced catastrophic out-of-pocket payments (defined as spending more than 30% of household income for cancer-related costs) in the year after diagnosis \[[@CR10], [@CR11]\].

In addition to economic outcomes, key outcomes considered were health-related quality of life (HRQoL) and psychological distress 1 year after diagnosis \[[@CR9]\]. While treatment has generally been completed a year after diagnosis, the cancer burden may still be significant due to short- and long-term sequelae that impair HRQoL \[[@CR12], [@CR13]\]. Cancer survivors are at increased risk of cancer-related fatigue and psychological symptoms \[[@CR14]--[@CR19]\]. Poor health is an important barrier to get back to work or take up activities of daily living after treatment \[[@CR20], [@CR21]\], thereby putting individuals and families at risk of impoverishment. However, few studies have been conducted in LMICs, and awareness of health issues affecting cancer survivors is still low \[[@CR22], [@CR23]\]. A better understanding of HRQoL and psychological distress in cancer survivors can raise awareness, promote the development of policies in cancer survivorship care, and facilitate better targeted use of limited resources \[[@CR8]\].

The main objectives of this study were to assess HRQoL and the prevalence of psychological distress amongst cancer survivors in LMICs in Southeast Asia, 1 year after diagnosis. Secondary objectives were to identify demographic, clinical and socioeconomic predictors of poor HRQoL and psychological distress.

Methods {#Sec2}
=======

Setting and participants {#Sec3}
------------------------

The ACTION study was a prospective longitudinal study in which cancer patients from eight LMICs of ASEAN (Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand and Vietnam) were invited to participate. Detailed methods have been published previously \[[@CR9]\]. In brief, 9513 first-time cancer patients were consecutively recruited from 47 sites, of which more than 95% were public hospitals. Participants, aged 18 years and over, were interviewed by study staff at baseline (within 12 weeks after clinical diagnosis) and at 3 and 12 months after diagnosis. One year after diagnosis, 29% (*n* = 1993) of the initial study population had died and 24% (*n* = 2271) were lost to follow-up. The remaining 5249 survivors were contactable at 12 months and were included in this report.

The ACTION study was approved by the University of Sydney Human Research Ethics Committee. Approvals from local institutional ethics committees and other regional or national regulatory bodies were obtained prior to the initiation of the study in any site (Additional file [1](#MOESM1){ref-type="media"}). Written informed consent, complying with local, regional, and national requirements, was obtained from all participants prior to entry into the study.

Patient-reported health outcomes {#Sec4}
--------------------------------

Cancer-specific HRQoL was assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 (version 3.0). Official translations were available for all countries except Laos and Cambodia \[[@CR24]\]. The following were assessed: global health status, role function, cognitive function, physical function, emotional function, social function, fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite, constipation, and diarrhea. Scores are presented on a linear scale of 0 to 100. Higher scores correspond to better HRQoL in the function and global health scales, whereas higher scores in symptom scales and items represent more problems with symptoms \[[@CR25]\].

Generic HRQoL was assessed using the EuroQol-5 dimensions questionnaire (EQ-5D) \[[@CR26]\], which comprises five items relating to problems in mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The EQ-5D index provides a valuation of HRQoL in which full health is scored at 1, and death is 0 \[[@CR27]\]. Official translations were provided by the EuroQoL group for all countries except Laos and Cambodia, covering 96% of the study population.

Psychological distress was measured using the Hospital Anxiety and Depression Scale (HADS), which measures generalized anxiety and depression experienced during the past week with two subscales: anxiety (HADS-A) and depression (HADS-D) \[[@CR28]\]. The HADS is a self-report instrument and has been widely used in cancer patients \[[@CR29]\]. A cut-off of ≥ 8 on the HADS-D scale and ≥ 9 on the HADS-A was used to indicate cases of least mild depression and anxiety, respectively \[[@CR29]\]. Official translations were available for Indonesia, Malaysia, Philippines and Thailand, covering 63% of the study population.

In cases where a formal translation was not available, questionnaires were translated using forward-translation and back-translation following WHO guidelines for the process of translation of questionnaires \[[@CR30]\].

Predictor variables {#Sec5}
-------------------

We considered a range of demographic, socioeconomic and clinical variables as putative predictors of HRQoL and psychological distress. The demographic and socioeconomic variables considered were collected through self-reported questionnaires and relate to the time of entry to the study (baseline). Demographic variables considered were age, sex, marital status, and country of residence. Socioeconomic variables considered were household income (grouped into low (0--75% of mean national income), middle (75--125%) and high income (\>125%)), economic hardship (whether in the 12 months previous to baseline they were unable to make necessary household payments or needed assistance to do so \[[@CR31]\]), employment status (paid work), health insurance status, and highest level of education attained. Clinical variables obtained from medical records at baseline comprised cancer site, cancer stage at diagnosis (clinical TNM classification), and pre-existing chronic conditions. Treatment modality was ascertained at the end of study (12 months after baseline).

Statistical analyses {#Sec6}
--------------------

Descriptive statistics were used to report the distribution of demographic, socioeconomic and clinical characteristics of the full study population, and separately by sex. The distribution of HRQoL scores and prevalence of anxiety and depression at 12 months was determined for the study population, the most common cancer types (those with more than 200 cases), and other potential predictors of these outcomes. Evidence-based guidelines for the interpretation of differences in EQ-5D and QLQ-C30 scores were used \[[@CR32], [@CR33]\]. For example, an observed mean difference of \< 4 points on the QLQ-C30 global health scale was considered trivial and unlikely to have clinical relevance \[[@CR34]\]. General linear models for HRQoL endpoints and multiple logistic regression for anxiety and depression were used to determine the association between predictor variables and study outcomes. To limit the number of tests and its associated increased likelihood of a type I error occurring, multivariable analyses were conducted for selected outcomes; global health, physical function, emotional function, fatigue, and pain. These outcomes are hypothesized to be most distinctive for the long-term health of different subgroups of cancer patients \[[@CR21]\]. Stratified analyses explored the impact of predictor variables across the most common cancer types.

Results {#Sec7}
=======

Study sample {#Sec8}
------------

Characteristics of the 5249 survivors followed-up at 12 months are shown in Table [1](#Tab1){ref-type="table"}; Additional file [2](#MOESM2){ref-type="media"}: Table S1A details the characteristics by sex. The mean age of the study population was 52 years (range, 18--100) and 69% were female. Almost half of the participants (*n* = 2365, 45%) were from lower middle-income countries (Laos, Indonesia, Vietnam, and the Philippines), followed by upper middle-income countries (Malaysia and Thailand; *n* = 2199, 42%) and low-income countries (Cambodia and Myanmar; *n* = 685, 13%).Table 1Demographic, socioeconomic, and clinical characteristics of the study population (*n* = 5249)CharacteristicAllN%Age, years  \< 45156930 45--54157730 55--64136926  ≥ 6573214 Missing2\<1Sex Male161831 Female363169Marital status Married404777 Unmarried120223Level of education 0--6 years (primary)193237 7--12 years (secondary)216941  \> 12 years (tertiary)114822Country of residence Cambodia1313 Indonesia67313 Laos561 Malaysia136126 Myanmar55411 Philippines4589 Thailand83816 Vietnam117822Household income (of mean national income) Low164331 Med104820 High181535 Do not know/missing74314Health insurance status Yes224943 None299957 Missing1\< 1Experienced economic hardship in the year before diagnosis Yes264350 No260550 Missing1\< 1Paid work (patient level) before diagnosis (self-employed or for a wage) Yes248147 No276853Cancer site Mouth and pharynx57111 Esophagus49\< 1 Stomach1433 Colon and rectum55211 Liver26\< 1 Pancreas26\< 1 Trachea, bronchus and lung2264 Melanoma18\< 1 Breast165432 Cervix59811 Uterus1272 Ovary1232 Prostate27\< 1 Bladder20\< 1 Lymphomas and multiple myeloma2415 Leukemia1954 Other malignant neoplasms61712 Missing36\< 1Cancer (TNM) stage at diagnosis Stage I4378 Stage II119023 Stage III98419 Stage IV56111 None (hematological cancers)4368 Missing164131Treatment^a^ Surgery293156 Radiotherapy243846 Chemotherapy355068 Hormonal therapy4969Pre-existing chronic conditions (as reported in medical files) 0403277 183916  ≥ 23527 Missing26\< 1^a^Categories are not mutually exclusive since most patients received a combination of treatments

The most common cancer types were breast (32%), cervix (11%), mouth and pharynx (11%), colon and rectum (11%), and lymphomas (5%). Among patients with available data on cancer stage (n = 3172), 14% presented with stage I, 38% with stage II, 31% with stage III, and 17% with stage IV cancers, whereas hematological cancers were diagnosed in 436 patients (8%). Fifty-six percent of participants had surgery as part of treatment, 68% had chemotherapy and 46% had radiotherapy (not mutually exclusive).

In females, cancer of the breast (45%) and cervix (17%) were most common. Among males, mouth (23%) and colorectal (19%) cancer were most common. Of female participants, 35% presented with stage I or II cancer compared to only 18% of males.

Patient-reported health outcomes {#Sec9}
--------------------------------

A year after diagnosis, the mean global health score for survivors was 66.2 (SD 22.0) on the QLQ-C30 (Table [2](#Tab2){ref-type="table"}). Scores on function scales ranged from 73.7 (SD 26.6) for social functioning, to 79.0 (SD 22.8) for physical function and 86.2 (SD 20.7) for cognitive functioning. In terms of symptoms, highest scores (i.e., more symptoms) were reported for fatigue (24.7), pain (21.4), and insomnia (21.2). The mean index score on the EQ-5D was 0.74 (SD 0.23). In terms of psychological distress, a year after diagnosis, anxiety was seen in 37% of survivors and depression in 46%.Table 2Health-related quality of life (HRQoL) and psychological distress 1 year after diagnosisAll cancers (*n* = 5249)HRQoL Cancer-specific HRQoL (EORTC QLQ-C30)MeanSD  Global health66.222.0  Physical function79.022.8  Emotional function76.224.8  Role function74.828.8  Cognitive function86.220.7  Social function73.726.6  Fatigue24.725.2  Nausea/vomiting10.718.9  Pain21.425.4  Dyspnea13.922.8  Insomnia21.227.5  Appetite loss20.027.9  Constipation11.321.4  Diarrhea7.817.1 Generic HRQoL (EQ-5D)  Index score0.740.23Psychological distressN% HADS-A: Anxiety193337 HADS-D: Depression239446*HADS* Hospital Anxiety and Depression Scale

Poorer outcomes, i.e., lowest HRQoL scores and highest symptom scores, were consistently seen in lung cancer and lymphoma patients (Fig. [1a--c](#Fig1){ref-type="fig"}, Additional file [2](#MOESM2){ref-type="media"}: Table S2A). Mean QLQ-C30 global health scores were respectively 56.5 (SD 23.2) and 52.8 (SD 27.2) for lung and lymphoma, compared to 74.2 (SD 17.7) and 69.7 (SD 19.4) for cancers of the cervix and breast. Similarly, the proportion of patients reporting moderate or severe problems on the EQ-5D domains was highest for lung cancer and lymphomas (Fig. [1d](#Fig1){ref-type="fig"}). The EQ-5D index scores for lung cancer and lymphomas were 0.63 (SD 0.24) and 0.69 (SD 0.24), respectively, compared to 0.76 (SD 0.21) and 0.78 (SD 0.21) for cancers of the breast and cervix, respectively. The proportion of patients with psychological distress was also highest among lung and lymphoma cancer patients; 60% of these patients report depression and anxiety was seen in 50% of lung cancer patients and 58% of lymphoma patients. Highest HRQoL scores, lowest symptom burden and lowest prevalence of anxiety and depression were seen in patients with cancer of the cervix.Fig. 1Health-related quality of life and psychological distress among cancer survivors (n = 5249) 1 year after diagnosis. **a** EORTC QLQ-C30 function scales, **b** EORTC QLQ-C30 symptom scales, **c** HADS anxiety and depression: proportion of survivors with anxiety and depression), and **d** EQ-5D domains: proportion of survivors with moderate or severe problems

HRQoL outcomes and psychological distress for subgroups of patients are presented in Table [3](#Tab3){ref-type="table"}. Clinically meaningful differences in HRQoL scores (i.e., \> 4 points difference on EORTC scales) were seen between participants older than 65 years compared to those younger than 45 years (e.g., EQ-5D index of 0.67 (SD 0.25) vs. 0.76 (SD 0.22), physical function of 72.6 (SD 28.0) vs. 81.9 (SD 21.5)). Older participants also reported more anxiety (45% vs. 36%) and depression (56% vs. 43%) than participants younger than 45 years. Male cancer survivors reported lower HRQoL scores on the EQ-5D, the QLQ-C30 function scales, and for fatigue and pain, but mean differences are considered trivial \[[@CR34]\]. The prevalence of anxiety (42% vs. 35%) and depression (52% vs. 43%), however, is substantially higher in males than in females. The socioeconomic variables household income (low vs high), economic hardship, and not being in paid work were all associated with lower HRQoL scores, but differences were small. Nevertheless, a high income and paid work were associated with fewer cases of anxiety and depression. Health insurance was not associated with HRQoL and psychological distress.Table 3Demographic, socioeconomic, and clinical characteristics of the study population (*n* = 5249) and their associations with health-related quality of life (HRQoL) and psychological distress at 1 year after diagnosis as measured by the EORTC QLQ-C30, EQ-5D, and HADSHRQoLPsychological distressGeneric HRQoLCancer-specific HRQoL (EORTC QLQ-C30)EQ-5D index^a^Physical functionEmotional functionGlobal healthPainFatigueAnxietyDepressionMean (SD)Mean (SD)Mean (SD)Mean (SD)Mean (SD)Mean (SD)N (%)N (%)Age group, years  \< 450.76 (0.22)81.9 (21.5)77.8 (24.0)67.0 (23.0)19.2 (24.1)21.6 (24.0)570 (36)678 (43) 45--540.75 (0.22)80.9 (21.9)76.7 (24.2)67.5 (21.1)20.7 (25.7)23.5 (24.6)513 (33)663 (42) 55--640.73 (0.23)77.9 (22.1)75.8 (24.4)65.9 (21.0)22.1 (24.9)26.1 (24.9)519 (38)644 (47)  ≥ 650.67 (0.25)70.5 (26.1)72.6 (28.0)62.6 (23.3)31.4 (28.3)31.4 (28.3)330 (45)408 (56)Sex Female0.75 (0.22)80.1 (21.7)76.8 (24.4)66.2 (18.1)20.2 (24.5)23.9 (24.8)1262 (35)1560 (43) Male0.71 (0.24)76.5 (24.8)75.0 (25.5)62.3 (20.0)24.1 (27.0)26.6 (26.0)671 (42)834 (52)Marital status Married0.74 (0.23)79.2 (22.5)76.5 (24.3)66.7 (21.6)21.5 (25.3)24.6 (25.0)1501 (37)1845 (46) Not married0.73 (0.23)78.3 (23.6)75.5 (26.3)64.9 (23.5)21.1 (25.7)24.9 (26.1)432 (36)549 (46)Level of education 0--6 years (primary)0.73 (0.23)77.8 (24.1)77.1 (24.8)68.1 (21.6)21.5 (26.1)24.2 (25.7)641 (33)849 (44) 7--12 years (secondary)0.74 (0.23)79.1 (21.8)75.4 (24.2)64.3 (21.4)22.1 (24.8)25.7 (24.7)908 (42)1088 (50)  \> 12 years (tertiary)0.75 (0.22)80.8 (22.2)76.3 (25.8)66.8 (23.5)19.9 (25.2)23.7 (25.4)384 (33)457 (40)Household income Low (0--75%)0.71 (0.23)76.5 (24.9)74.0 (25.8)64.9 (23.2)23.3 (27.0)25.4 (26.4)712 (43)818 (50) Med (75--125%)0.72 (0.23)78.3 (21.8)76.0 (24.3)65.1 (22.1)21.5 (24.9)23.6 (24.2)420 (40)526 (50) High (\> 125%)0.78 (0.22)81.6 (21.2)78.0 (24.4)67.1 (20.7)18.7 (23.8)24.0 (24.5)510 (28)685 (38)Health insurance Yes0.75 (0.22)78.6 (24.2)76.9 (24.8)68.0 (21.4)22.7 (26.3)25.9 (26.1)813 (36)1022 (46) No0.73 (0.23)79.3 (21.6)75.7 (24.8)64.9 (22.4)20.4 (24.6)23.8 (24.5)1120 (38)1372 (46)Economic hardship Yes0.73 (0.23)77.1 (24.9)75.2 (25.9)67.8 (22.0)23.6 (27.5)26.6 (27.1)949 (36)1217 (46) No0.75 (0.22)80.9 (20.2)77.3 (23.6)64.7 (22.0)19.2 (22.8)22.8 (23.0)984 (38)1177 (45)Paid work Yes0.75 (0.22)80.9 (22.2)77.0 (24.9)67.3 (21.8)19.5 (25.1)22.7 (24.8)787 (32)996 (40) No0.72 (0.23)77.2 (23.2)75.5 (24.7)65.3 (22.2)23.1 (25.6)26.5 (25.5)1146 (42)1398 (51)Cancer stage at diagnosis Stage I0.81 (0.20)85.7 (15.8)82.3 (18.9)74.2 (18.3)12.5 (18.0)16.6 (19.5)99 (23)141 (32) Stage II0.79 (0.21)83.6 (18.6)79.9 (22.8)71.5 (18.9)15.7 (21.1)20.0 (22.0)323 (27)424 (36) Stage III0.75 (0.22)79.6 (23.3)76.0 (25.3)69.0 (21.6)20.4 (26.1)24.0 (25.6)296 (30)400 (41) Stage IV0.65 (0.24)69.8 (29.0)63.4 (34.7)57.0 (23.8)32.6 (32.0)36.6 (32.3)265 (47)327 (58) None (hematological cancers)0.67 (0.23)77.4 (18.6)77.9 (18.6)44.7 (26.8)21.1 (21.0)22.1 (19.6)308 (71)313 (72)Treatment^b^  Surgery0.78 (0.22)82.1 (21.2)78.7 (25.2)69.9 (20.5)17.9 (24.5)22.1 (25.3)1051 (36)1051 (36)  No surgery0.68 (0.23)74.8 (24.1)72.9 (24.1)61.4 (23.2)25.7 (25.8)27.9 (24.9)1123 (51)1322 (60)  Radiotherapy0.73 (0.22)78.6 (22.5)76.1 (24.4)67.0 (21.7)20.1 (24.9)25.3 (25.0)881 (36)1123 (46)  No radiotherapy0.74 (0.23)79.2 (22.9)76.2 (25.3)65.5 (22.5)22.5 (25.8)24.0 (25.5)1026 (38)1248 (46)  Chemotherapy0.73 (0.23)78.6 (22.7)75.2 (25.2)65.0 (22.9)21.7 (25.6)25.3 (25.6)1330 (38)1652 (47)  No chemotherapy0.76 (0.23)79.7 (23.0)78.4 (23.9)69.0 (20.2)20.2 (24.7)23.1 (24.6)580 (36)732 (45)Pre-existing chronic conditions 00.74 (0.23)79.6 (22.4)76.8 (24.0)66.3 (22.0)21.1 (25.1)24.0 (24.8)1503 (37)1853 (46) 10.74 (0.23)79.0 (22.8)77.2 (24.7)66.5 (21.7)20.4 (24.8)24.2 (24.9)266 (32)357 (43)  ≥ 20.67 (0.23)71.5 (25.1)67.5 (31.7)64.8 (23.7)27.5 (29.5)34.6 (29.3)159 (45)177 (50)^a^Index scores based on Thai tariff^b^Categories are not mutually exclusive since most patients received a combination of treatments

Cancer stage at diagnosis and co-morbidities were associated with HRQoL and psychological distress. Directions were as expected; a more advanced cancer stage and more than two pre-existing chronic conditions were associated with lower HRQoL scores (all endpoints) and more cases of psychological distress.

Findings from the multivariable linear model showed that, in general, predictor variables, except treatment modalities (radiotherapy and chemotherapy), had a significant independent impact on HRQoL and psychological distress (Table [4](#Tab4){ref-type="table"}). HRQol scores decreased, and the odds of psychological distress increased, with increasing age. Males had lower emotional function scores and higher odds of psychological distress compared to females. Other HRQoL outcomes were not affected by sex. Being married (vs. unmarried) positively impacted on physical and emotional function (QLQ-C30), but not on global health, the EQ-5D index, and psychological distress. Cancer stage at diagnosis was the strongest predictor with clinically meaningful reductions in HRQoL and psychological distress; stage IV and hematological cancers were predictive of severely impaired HRQoL (all endpoints) and the odds of having anxiety or depression. Having multiple chronic conditions was an important predictor for poor HRQoL and psychological distress. A high income (vs. low) and being in paid work positively impacted on most HRQoL outcomes and were associated with lower odds of psychological distress. Health insurance was associated with higher global health scores, but lower scores for physical function, pain and fatigue, and slightly higher odds of depression.Table 4Standardized betas of multiple linear regression analyses and logistic linear regression analyses evaluating the association of independent variables with HRQoL and psychological distress across all cancers (*n* = 5249)Full modelEQ-5D indexPhysical functionEmotional functionGlobal healthPainFatigueAnxietyDepressionAge−0.21 (−0.28 to −0.15)−0.25 (−0.31 to −0.18)−0.17 (−0.25 to −0.09)−0.12 (−0.19 to −0.05)0.20 (0.12 to 0.28)0.27 (0.19 to 0.35)1.01 (1.00 to 1.02)1.01 (1.01 to 1.02)Sex−1.13 (−2.90 to 0.63)−0.91 (−2.64 to 0.82)−3.15 (−5.18 to −1.13)0.73 (−1.01 to 2.47)0.44 (−1.50 to 2.38)1.16 (−0.79 to 3.11)1.43 (1.24 to 1.62)1.20 (1.02 to 1.37)Marital status0.65 (−1.17 to 2.48)1.94 (0.16 to 3.73)2.22 (0.13 to 4.31)1.36 (−0.44 to 3.15)−1.42 (−3.42 to 0.59)−2.04 (−4.05 to −0.03)1.18 (0.98 to 1.37)0.93 (0.75 to 1.12)Level of education PrimaryRefRefRefRefRefRefRefRef Secondary−2.70 (−4.55 to −0.86)−2.17 (−3.98 to −0.37)−5.16 (−7.27 to −3.04)−5.63 (−7.45 to −3.81)3.17 (1.14 to 5.20)4.39 (2.36 to 6.43)2.24 (2.04 to 2.44)1.79 (1.60 to 1.97) Tertiary−4.07 (−6.30 to −1.84)−2.82 (−5.00 to −0.63)−6.04 (−8.60 to −3.48)−3.68 (−5.88 to −1.48)3.48 (1.02 to 5.94)5.44 (2.97 to 7.90)1.81 (1.56 to 2.05)1.34 (1.12 to 1.57)Household income LowRefRefRefRefRefRefRefRef Medium−0.83 (−2.90 to 1.24)−0.20 (−2.23 to 1.83)0.87 (−1.50 to 3.24)−0.39 (−2.43 to 1.65)0.22 (−2.06 to 2.50)−0.27 (−2.56 to 2.01)0.90 (0.68 to 1.11)1.18 (0.98 to 1.39) High3.68 (1.78 to 5.58)2.51 (0.64 to 4.37)2.75 (0.57 to 4.94)−0.09 (−1.97 to 1.79)−2.49 (−4.59 to −0.39)−0.39 (−2.49 to 1.71)0.48 (0.28 to 0.69)0.74 (0.55 to 0.93) Health insurance1.16 (−0.47 to 2.79)−2.21 (−3.80 to −0.62)0.09 (−1.78 to 1.96)2.46 (0.85 to 4.06)3.88 (2.09 to 5.67)3.74 (1.94 to 5.54)1.13 (0.95 to 1.30)1.21 (1.05 to 1.38) Economic hardship−0.63 (−2.23 to 0.98)−3.28 (−4.86 to −1.71)−2.35 (−4.19 to −0.50)2.44 (0.86 to 4.03)3.41 (1.64 to 5.18)3.85 (2.07 to 5.62)0.81 (0.64 to 0.99)0.94 (0.78 to 1.10) Paid work2.04 (0.40 to 3.68)3.11 (1.50 to 4.72)1.72 (−0.16 to 3.60)2.76 (1.14 to 4.37)−3.17 (−4.98 to −1.37)−3.25 (−5.06 to −1.44)0.66 (0.48 to 0.83)0.68 (0.51 to 0.84)Cancer stage at diagnosis Stage IRefRefRefRefRefRef Stage II−1.43 (−4.06 to 1.20)−2.09 (−4.66 to 0.48)−1.37 (−4.38 to 1.65)−2.14 (−4.73 to 0.45)2.96 (0.07 to 5.86)2.79 (−0.11 to 5.69)1.30 (1.00 to 1.60)1.12 (0.86 to 1.39) Stage III−3.42 (−6.18 to −0.66)−4.45 (−7.15 to −1.75)−4.77 (−7.94 to −1.61)−4.09 (−6.81 to −1.37)6.32 (3.29 to 9.36)5.97 (2.93 to 9.02)1.30 (0.99 to 1.61)1.21 (0.93 to 1.49) Stage IV−13.34 (−16.40 to −10.27)−14.73 (−17.73 to −11.73)−18.61 (−22.13 to −15.10)−15.14 (−18.16 to −12.11)19.29 (15.91 to 22.67)20.01 (16.63 to 23.40)2.73 (2.40 to 3.07)2.29 (1.98 to 2.60) Hematological−8.53 (−12.07 to −5.00)−7.58 (−11.04 to −4.12)−2.27 (−6.33 to 1.78)−25.76 (−29.25 to −22.27)7.89 (3.99 to 11.78)5.68 (1.78 to 9.59)5.05 (4.67 to 5.44)3.06 (2.70 to 3.42)Treatment Surgery7.10 (5.34 to 8.85)4.48 (2.77 to 6.20)4.22 (2.21 to 6.23)2.27 (0.54 to 4.00)−4.81 (−6.74 to −2.88)−3.29 (−5.22 to −1.35)0.39 (0.21 to 0.57)0.40 (0.23 to 0.58) Radiotherapy−0.44 (−2.01 to 1.14)−0.27 (−1.81 to 1.27)0.13 (−1.68 to 1.94)0.10 (−1.45 to 1.66)1.35 (−0.39 to 3.08)0.53 (−1.21 to 2.27)1.11 (0.94 to 1.28)1.05 (0.89 to 1.20) Chemotherapy−3.47 (−5.29 to −1.65)−0.58 (−2.36 to 1.20)−1.56 (−3.65 to 0.52)−1.20 (−3.00 to 0.59)−0.45 (−2.45 to 1.56)0.41 (−1.60 to 2.42)0.93 (0.74 to 1.12)1.02 (0.84 to 1.20)No. of pre-existing chronic conditions−2.32 (−3.44 to −1.19)−2.51 (−3.61 to −1.41)−2.92 (−4.21 to −1.63)−0.22 (−1.33 to 0.89)2.30 (1.06 to 3.54)3.41 (2.17 to 4.65)1.17 (1.06 to 1.29)1.13 (1.02 to 1.24)Age and number of pre-existing chronic conditions were entered as a continuous variable in the regression models. Other variables were sex: females vs. males; marital status: married vs. unmarried; level of education: primary vs. secondary vs. tertiary; household income: low vs. medium vs. high; health insurance: no vs. yes; economic hardship: yes vs. no; paid work: no vs. yes; cancer stage at diagnosis; stage I vs. stage II vs. stage III vs. stage IV; treatment: surgery vs. no surgery, radiotherapy vs. no radiotherapy; chemotherapy vs. no chemotherapy

Multivariable models stratified by cancer type showed that stage at diagnosis was the most important predictor of HRQoL and psychological distress across breast, cervical, lung, mouth, colorectal cancer, and lymphomas (Additional file [2](#MOESM2){ref-type="media"}: Tables S4A--F). In addition, a range of socioeconomic variables were associated with HRQoL endpoints and psychological distress across these cancer types. Results of the stratified analyses must be interpreted with caution because the models (except for breast cancer) were generally underpowered and could therefore only detect the strongest predictors.

Discussion {#Sec10}
==========

One year after diagnosis, we identified impaired HRQoL and a prevalence of anxiety of 37% and depression of 46% amongst cancer survivors in LMICs in Southeast Asia. Differences in HRQoL and psychological distress were observed based on age, sex, household income, cancer type, and stage at diagnosis. In general, older patients, males, patients with lung cancer or lymphomas, an advanced stage at diagnosis, low income status, and those not in paid work reported lowest HRQoL scores and were most likely to report anxiety and depression. Female patients with cancer of the breast and cervix showed the most favorable outcomes reflecting a better prognosis for these type of cancers \[[@CR2]\]. An advanced cancer stage at diagnosis was the strongest independent predictor of poor HRQoL outcomes and psychological distress. In addition, increasing age, having multiple chronic conditions, and several socioeconomic variables were identified as being independently associated with poor outcomes.

Inevitably, comparison of HRQoL and psychological distress with earlier studies is rough due to the varying settings, cancer types, and measures used. We are aware of few studies among cancer survivors in Southeast Asia or other LMICs \[[@CR19], [@CR35]\]. Most research on cancer survivorship has been conducted in high-income settings where patients were more likely to receive a timely diagnosis, optimal treatment, follow-up, and survivorship care. Survival rates, therefore, differ drastically between countries but, regardless of setting, many cancer survivors experience symptom burden, loss of HRQoL, and (at least mild) psychological distress in the first year after treatment \[[@CR12], [@CR13], [@CR36], [@CR37]\]. Cancer stage is widely recognized as an important clinical determinant of HRQoL in cancer survivors \[[@CR12], [@CR19], [@CR37]--[@CR42]\]. A diagnosis of lung cancer and having comorbid conditions are also associated with a high symptom burden and low HRQoL \[[@CR12], [@CR13], [@CR36], [@CR37]\]. In both low- and high-income settings, socioeconomic disparity in cancer survivors has been associated with poor HRQoL \[[@CR12], [@CR13], [@CR35], [@CR42]--[@CR45]\] and psychological distress \[[@CR46], [@CR47]\]. Possible explanations may be poorer recognition of cancer symptoms and more barriers to access appropriate and timely healthcare services by patients with low socioeconomic status \[[@CR48]\]. Patients with a poor socioeconomic position are also less likely to receive appropriate follow-up care and discuss concerns with their healthcare providers \[[@CR49]\]. Our study has generally confirmed the relationship between poor socioeconomic position (e.g., a low household income, not being in paid work, and having experienced economic hardship) and impaired HRQoL and psychological distress, with one exception; primary education only was consistently associated with better study outcomes. While the absence of an association between education and HRQoL has been reported in certain cancer types and countries \[[@CR36], [@CR50]\], few studies find this inverse relationship between education and HRQoL \[[@CR51]\]. To rule this out as a chance finding, this observation warrants further investigation. Another notable finding was that patients with health insurance were not necessarily better off than those without. These results, however, need to be interpreted with caution as we did not have data on benefit packages provided by the various health insurance schemes and associated processes of care. For example, Malaysia has achieved universal coverage that includes cancer care, but healthcare is provided through public health facilities that may have long waiting times \[[@CR52]\].

Our study has a number of limitations. First, participation in the study was voluntary and, as such, the proportion of cases observed for individual cancers were not representations of population incidences. Clinicians responsible for enrolling patients into the study appear to have under-recruited those with the most virulent types of cancer such as lung and liver cancers. Second, by one year, 23% of the original study population had died and 24% were lost to follow-up. The high loss to follow-up is unfortunate, but not surprising, and may have introduced response bias. It is plausible that patients with poor HRQoL after treatment may have been less interested or too ill to continue participation; patients who completed the 12 months follow-up were more likely to have stage I or II cancer (Additional file [2](#MOESM2){ref-type="media"}: Table S1B). These first two limitations may have resulted in an underestimate of HRQoL and the prevalence of psychological distress in this patient population. Third, while HRQoL and psychological distress were measured upon study entry (within 12 weeks after clinical diagnosis), and at 3 and 12 months, we did not report change scores since the first two measurements are likely to reflect the type and timing of treatment (e.g., recovery from surgery, having second line treatment or just supportive care) as opposed to underlying HRQoL, and thus changes in scores may be transient fluctuations caused by treatment course. Fourth, while widely endorsed as one of the best available measures of anxiety and depression, the use of the HADS across languages and cultures has recently been criticized, e.g., there may be an unknown influence of linguistic and cultural factors on cut-points for anxiety and depression \[[@CR53]\]. As such, there may be concerns that items in the translated version may differ conceptually to the original version. In our study, this risk may been pronounced in approximately 36% of the sample where official translations of the original questionnaires were not available and we had to undertake our own. Results presented here regarding prevalence must therefore be interpreted with caution. Nevertheless, the HADS was used for the purpose of subgroup comparisons and correlations rather than a screening tool, and therefore results provide useful insight into groups of patients with higher prevalence of anxiety and depression as well as risk factors. Finally, it was not possible to compare mean HRQoL scores of the cancer population to scores of the general population due to the lack of reference scores for Southeast Asia.

Despite limitations, our study is unique in being observational, including a large population of cancer survivors in an LMIC setting, and using a range of well-validated measures that characterize wellbeing in cancer patients. Until now, high-quality data on the quality of life lived with cancer have been lacking in ASEAN populations. Results from this study should encourage governments in the region to take action to develop national cancer control strategies and extend national health insurance initiatives to remove barriers to early diagnosis and prompt treatment \[[@CR2], [@CR8]\]. Awareness education and screening for detectable cancers may result in a larger proportion of patients presenting with early stage cancers that are more likely to be able to receive curative and less invasive treatment options, leading to cost savings and a reduction in mortality \[[@CR54], [@CR55]\], as well as to better HRQoL and lower levels of psychological distress among survivors, as found herein. Following (early) diagnosis, governments should ensure access to appropriate and quality treatment, including medication for cancer \[[@CR6]\]. The focus of this paper, however, is on the needs of cancer survivors. Supportive and survivorship care, i.e., the prevention and management of the adverse effects of cancer and its treatment are increasingly recognized as critical components of quality cancer care and cancer control programs. Yet, in resource-constrained health systems, survivorship care is often overlooked \[[@CR56]--[@CR58]\]. Consensus statements and recommendations have been developed, mainly for breast cancer, to illustrate how health systems in LMICs can provide appropriate cancer care, including survivorship care, taking resource constraints into account \[[@CR22], [@CR56], [@CR59]\]. Most recommendations can be generalized to other cancers. First, at the health system level, appropriate follow-up care (in terms of frequency and intensity) after completion of initial treatment is needed to monitor for possible recurrences or new cancers and adverse effects of treatments \[[@CR22]\]. Scheduled follow-up visits, and the name of the health professional responsible for post-treatment care, should be documented in a patient's individual care and survivorship plan \[[@CR60]\]. This document should also include details of the patient's treatment protocol so that potential specific treatment-related complications and long-term physical side effects can be considered \[[@CR56], [@CR59]\]. Importantly, assessment of psychosocial needs, including depression, anxiety, emotional distress, and changes to social roles, should be part of the follow-up care provided. Health professionals need (additional) education about the recognition and management of long-term physical complications and psychosocial complications of survivorship \[[@CR22]\]. In addition, patients must be educated on symptoms of disease recurrence and lifestyle modifications to reduce cancer risk and improve quality of life \[[@CR22], [@CR59]\]. Our findings emphasize that patients in poor socioeconomic positions (e.g., low income, unemployed) and patients with late-stage cancers are at highest risk for poor HRQoL and psychological distress and therefore policies are needed to address the financial burden of treatment, including the expansion of national insurance programs and other social safety nets to offset the indirect costs incurred by patients and their families. Survivorship interventions should address wide aspects of wellbeing and are ideally implemented as part of routinely offered programs of care. Governments and research organizations should encourage this type of cancer (survivorship) research and accelerate the translation of research findings into clinical and public health practice \[[@CR6]\].

Conclusions {#Sec11}
===========

This study provides valuable insight into the cancer burden in terms of HRQoL and psychological distress and risk factors for poor outcomes in low- and middle-income settings. Improving cancer awareness, early detection, prompt treatment, and appropriate survivorship care are the major public health and clinical approaches to improve the health and wellbeing of cancer survivors. Importantly, this study demonstrates that supportive interventions for cancer patients that address wider aspects of patient wellbeing are needed, including government initiatives to address the economic burden associated with treatment. Results can be used to support policies geared towards survivorship care and inform research evaluating supportive interventions.
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